$40.58
0.220.55%
At close: Jan 16, 4:00 PM EST
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Comments
Loading...
Virtus LifeSci Biotech Clinical Trials ETF (BBC) Stock Price, Quote, News & History
BBCARCA
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
36.50M
Fund Score
Key Statistics
Open
$40.53
High
$41.04
52 Wk High
$41.61
AUM
36.50M
Dividend
$0.66
Ex-Div Date
Dec 22, 2025
Volume
14.29K
Market Cap
$1.84B
Mgmt Fee
0.79%
P/E Ratio
21.31
Prev. Close
$40.36
Low
$40.05
52 Wk Low
$13.42
Shares Out
400.00K
Yield
1.62%
Div. Freq
-
Avg. Volume Daily
31.01K
Beta
0.91
Avg. Expense Ratio
0.79%
P/B Ratio
2.96
Recent Virtus LifeSci Biotech Clinical Trials ETF News
FAQ
Q
How do I buy Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
You can purchase shares of Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) through any online brokerage.
Q
Who are Virtus LifeSci Biotech Clinical Trials ETF (BBC) competitors?
A
There are no as such competitors for Virtus LifeSci Biotech Clinical Trials ETF.
Q
What is the forecast, or price target, for Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
There is no analysis for Virtus LifeSci Biotech Clinical Trials ETF to provide a consensus price target.
Q
What is the current price for Virtus LifeSci Biotech Clinical Trials ETF (BBC)?
A
The stock price for Virtus LifeSci Biotech Clinical Trials ETF (ARCA: BBC) is $40.58 last updated January 16, 2026 at 8:00 PM EST.
Q
Does Virtus LifeSci Biotech Clinical Trials ETF (BBC) pay a dividend?
A
There are no upcoming dividends for Virtus LifeSci Biotech Clinical Trials ETF.
Q
When is Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) reporting earnings?
A
Virtus LifeSci Biotech Clinical Trials ETF does not have any upcoming earnings scheduled.
Q
Is Virtus LifeSci Biotech Clinical Trials ETF (BBC) going to split?
A
There is no upcoming split for Virtus LifeSci Biotech Clinical Trials ETF.
Key Statistics
Open
$40.53
High
$41.04
52 Wk High
$41.61
AUM
36.50M
Dividend
$0.66
Ex-Div Date
Dec 22, 2025
Volume
14.29K
Market Cap
$1.84B
Mgmt Fee
0.79%
P/E Ratio
21.31
Prev. Close
$40.36
Low
$40.05
52 Wk Low
$13.42
Shares Out
400.00K
Yield
1.62%
Div. Freq
-
Avg. Volume Daily
31.01K
Beta
0.91
Avg. Expense Ratio
0.79%
P/B Ratio
2.96
About
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 16, 2014 |
| Managers | Matthew B. Brown Seth Kadushin |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
Investment Policy
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| NUVB | Nuvation Bio Inc | 2.15% |
| CELC | Celcuity Inc Com | 4.03% |
| TERN | Terns Pharmaceuticals ... | 3.41% |
| PRAX | Praxis Precision Medic... | 2.07% |
| GLUE | Monte Rosa Therapeutic... | 1.63% |
| ARWR | Arrowhead Pharmaceutic... | 1.86% |
| MBX | Mbx Biosciences Inc Co... | 1.61% |
| OLMA | Olema Pharmaceuticals ... | 3.48% |
| COGT | Cogent Biosciences Inc | 2.81% |
| MAZE | Maze Therapeutics Inc | 1.43% |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2026 Benzinga | All Rights Reserved